

14 Sep 2020 |

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by *Scrip*.

Take a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering key developments in the business week ended 11 September 2020.

In focus this time are a high-profile pause in a closely-watched coronavirus vaccine trial, one CEO's views on the pricing of COVID-19 interventions, a big Chinese oncology deal, promising results in asthma and an update on the fast-evolving migraine market.

Stories mentioned in this episode:

(Also see "[AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector](#)" - Scrip, 9 Sep, 2020.)

(Also see "[Merck CEO Stresses Need For 'Fair Return' On COVID-19 Interventions](#)" - Scrip, 7 Sep, 2020.)

(Also see "[\\$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map](#)" - Scrip, 4 Sep, 2020.)

(Also see "[Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma](#)" - Scrip, 8 Sep, 2020.)

(Also see "[Migraine Market Update: CGRP Inhibitors Slowly Gain Ground](#)" - Scrip, 7 Sep, 2020.)

[Click here to explore this interactive content online](#) 